ClinicalTrials.gg
Active, not recruitingNCT06109779Updated Oct 16, 2026

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

A Phase 3 interventional study of Rilvegostomig and Placebo in Biliary Tract Cancer, sponsored by AstraZeneca. Active, not recruiting at 176 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 16, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Biliary Tract Neoplasms by AstraZeneca — 4 open to participants now, 10 under way, 5 of them phase 3. Biliary Tract Neoplasms · AstraZeneca.

Enrollment
3rd of 14
760 · median 282
Started
2023
with 5 others
Phase 3
6 of 18
2 open now
Registered
12th of 18
by date

Among the 18 studies in Biliary Tract Neoplasms by AstraZeneca, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 6 that started in 2023, is one of 6 in phase 3, and was the 12th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 199 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

4 of the 18 studies in Biliary Tract Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Biliary Tract Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Read the detailed description

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/ gimeracil/ oteracil) or gemcitabine/cisplatin) as adjuvant treatment in participants with BTC after resection with curative intent. This study will be conducted in patients with BTC who are at risk of recurrence after resection with curative intent.

03

Conditions studied

  • Biliary Tract Cancer

Keywords

  • Adenocarcinoma of the biliary tract
  • Biliary tract Cancer
  • Gall bladder cancer
  • Intrahepatic Cholangiocarcinoma
  • Distal Cholangiocarcinoma
  • Perihilar Cholangiocarcinoma
  • Klatskin Tumors
  • Bile duct cancer
  • Immunotherapy
  • Cholangiocarcinoma
  • Rilvegostomig
  • S-1
  • Gemcitabine/cisplatin
  • Capecitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma (CCA) or muscle invasive gallbladder cancer (GBC)) after macroscopically complete resection (R0 or R1)
  • Provision of a tumor sample collected at surgical resection.
  • Randomization within 12 weeks after resection with adequate healing and removal of drains.
  • Confirmed to be disease-free by imaging within 28 days prior to randomization.
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Participants with locally-advanced, unresectable, or disease at initial diagnosis.
  • Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine neoplasms and nonepithelial tumors.
  • Any anti-cancer therapy for BTC prior to surgery
  • Active or prior documented or inflammatory disorders or any severe or uncontrolled systemic disease
  • Current or prior use of medication within 14 days before the first dose
  • Thromboembolic event within 3 months
  • Active or infection unless treated.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
760 participants (actual)

Study arms

  • Experimental
    Arm A

    Rilvegostomig IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)

    Drug: Rilvegostomig · Drug: Capecitabine · Drug: Gemcitabine/Cisplatin · Drug: S-1 [Tegafur/Oteracil/gimeracil]

  • Placebo comparator
    Arm B

    Placebo IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)

    Drug: Placebo · Drug: Capecitabine · Drug: Gemcitabine/Cisplatin · Drug: S-1 [Tegafur/Oteracil/gimeracil]

Interventions

  • Rilvegostomig IV (intravenous) Q3W

  • DrugPlacebo

    Placebo IV (intravenous) Q3W

  • Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice

  • DrugGemcitabine/Cisplatin

    Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle

  • DrugS-1 [Tegafur/Oteracil/gimeracil]

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles

06

What researchers measure

Primary outcomes

  1. Recurrence free survival (RFS) for Arm A vs. Arm B

    Recurrence-free survival (RFS) is defined as the time from randomization until the date of radiological recurrence guided by RECIST 1.1 or death due to any cause, whichever occurs first.

    Time frame: Approximately 5 years

Secondary outcomes

  1. Overall Survival (OS) for Arm A vs. Arm B

    Overall survival is defined as the time from randomization until the date of death due to any cause.

    Time frame: up to 7 years

Other outcomes

  1. Patient-reported tolerability Arm A vs. Arm B.

    Patient-reported tolerability is a multi-component endpoint defined as the proportion of participants in each arm reporting side effect bother, clinically meaningful impact on physical functioning and descriptive data on treatment-related symptoms.

    Time frame: Up to approximately 7 years.

  2. Progression Free Survival (PFS) following recurrence Arm A vs. Arm B.

    Progression-free survival following recurrence is defined as the time from randomization until the earliest progression event after the start of the first subsequent therapy or death.

    Time frame: Up to approximately 7years

07

Study locations

176 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Littleton, Colorado 80129, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Lexington, Kentucky 40506, United States
  • Research Site
    New Orleans, Louisiana 70121, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    Philadelphia, Pennsylvania 19144, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90035-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    Santo André, 09060-870, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Vancouver, British Columbia VSZ 4E6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    London, Ontario N6C 2R5, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Deyang, 618000, China
  • Research Site
    Fuzhou, 350005, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Guiyang, 550044, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Kunming, 650101, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Lishui, 323000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 2100008, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 201114, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430071, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Herlev, 2730, Denmark
  • Research Site
    Marseille, 13273, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Rennes, 35000, France
  • Research Site
    Strasbourg, 67033, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Bonn, 53127, Germany
  • Research Site
    Dortmund, 44137, Germany
  • Research Site
    Dresden, 01370, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Esslingen A. N., 73730, Germany
  • Research Site
    Frankfurt, 60488, Germany
  • Research Site
    Hamburg, 22763, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Leipzig, 4103, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    München, 81737, Germany
  • Research Site
    Münster, 48129, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Ulm, 89081, Germany

Showing the first 100 of 176 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagrouptrials.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Jan 2029, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Oct 31, 2023
StartActual
Dec 4, 2023
Primary completionEst.
Jan 2, 2029
CompletionEst.
May 3, 2030
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Research Site · Shatin, Hong Kong
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site removed
    Show 1 removed
    • Research Site · Shatin, Hong Kong
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06109779
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Dec 4, 2023
Primary completion
Jan 2, 2029 (estimated)
Completion
May 3, 2030 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilvegostomig

Start the discussion